Geffken Daniel E.
SEC-identified person · CIK 1314756 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Graybug Vision, INC. GRAY | Interim CFO | filed 2023 - 2024 |
| Phoenix Biotech Acquisition Corp. PBAX | Chief Financial Officer | filed 2021 - 2024 |
| Promis Neurosciences Inc. PMN | Chief Financial Officer | filed 2022 - 2023 |
| Windtree Therapeutics INC /DE/ dsco | Director | filed 2019 - 2023 |
| Sevion Therapeutics, Inc. SVOND | INTERIM CFO | filed 2021 - 2021 |
| Effector Therapeutics, Inc. LWAC | Chief Financial Officer | filed 2021 - 2021 |
| Nastech Pharmaceutical CO INC NSTK | Interim CFO | filed 2014 - 2014 |
| Cyberkinetics Neurotechnology Systems, Inc. CYKN.OB | Director | filed 2006 - 2006 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.